Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FLT4 | P35916 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714497 | 1.00 | FYN (0.43) | FYNTP53MAPTRAD52KMT2A | |
| SCHEMBL30505593 | 0.94 | TP53 (0.48) | FYNTP53MAPTRAD52KMT2A | |
| SCHEMBL29229255 | 0.94 | TP53 (0.48) | FYNTP53MAPTRAD52KMT2A | |
| SCHEMBL16212409 | 0.92 | TSPO (0.38) | FYNTP53MAPTRAD52KMT2A | |
| Trifluoroacetic Acid SCHEMBL28457409 | 0.91 | TSPO (0.43) | FYNTP53MAPTRAD52KMT2A | |
| SCHEMBL30505596 | 0.88 | FYN (0.52) | FYNTP53MAPTRAD52KMT2A | |
| SCHEMBL29229404 | 0.88 | FYN (0.52) | FYNTP53MAPTRAD52KMT2A | |
| SCHEMBL15876876 | 0.87 | TSPO (0.42) | FYNMAPTKMT2AMEN1KDR | |
| SCHEMBL643970 | 0.87 | FLT1 (0.39) | FYNKDREGFRERBB2FLT4 | |
| SCHEMBL2943758 | 0.85 | DHFR (0.43) | FYNKDRDHFRDHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217437-A | Dacotinib intermediate, dacotinib and preparation method of Dacotinib | 沈阳药科大学 | 2023-06-06 | — | — | CN | claimed |
| CN-114787151-B | Use of quinazoline derivatives or salts thereof, or pharmaceutical compositions thereof | 正大天晴药业集团股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-114787151-B | Use of quinazoline derivatives or salts thereof, or pharmaceutical compositions thereof | 正大天晴药业集团股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-116217437-A | Dacotinib intermediate, dacotinib and preparation method of Dacotinib | 沈阳药科大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-116217437-A | Dacotinib intermediate, dacotinib and preparation method of Dacotinib | 沈阳药科大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-114845723-A | Pharmaceutical composition comprising quinazoline derivative or salt thereof | 正大天晴药业集团股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114845723-A | Pharmaceutical composition comprising quinazoline derivative or salt thereof | 正大天晴药业集团股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114787151-A | Use of quinazoline derivative or salt thereof, or pharmaceutical composition thereof | 正大天晴药业集团股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20130274275-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER-LAMBERT COMPANY LLC | 2013-10-17 | — | — | US | disclosed |
| US-8466165-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
| EP-2406262-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2012-01-18 | — | — | EP | disclosed |
| EP-1746999-B1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | WARNER LAMBERT CO (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262877-A1 | HEAT TREATMENT APPARATUS | IHI CORPORATION (JP) | 2011-10-27 | — | — | US | disclosed |
| WO-2010104406-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-16 | — | — | WO | disclosed |
| US-7772243-B2 | 4-phenylamino-quinazolin-6-yl-amides | WARNER-LAMBERT COMPANY LLC (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100190977-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | FYN 306/4885TP53 433/4885MAPT 3315/4885 |
| US-20100190977-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | HRH4, HRH3, HRH2 | FYN 3979/4885TP53 275/4885MAPT 4679/4885 |
| US-20050250761-A1 | such as -Piperidin-1-yl-but-2-enoic acid [4(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yl]-amide, used as tyrosine kinase inhibitors, for the prevention of proliferative diseases, including cancer, atherosclerosis, restenosis, endometriosis and psoriasis | JAK1, JAK2, EDNRA | FYN 289/4885TP53 1771/4885MAPT 4367/4885 |
| US-20130274275-A1 | 4-PHENYLAMINO-QUINAZOLIN-6-YL-AMIDES | HRH4, HRH3, HRH2 | FYN 3979/4885TP53 275/4885MAPT 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.